only with
Healthcare
Small-cap - With a market cap of ₹215.21 Cr.
| EX-Date | Purpose |
|---|---|
| 08 11 2022 | Quarterly Results |
| 08 02 2023 | Rights Issue & Quarterly Results |
| 24 05 2023 | Audited Results |
| 03 08 2023 | Quarterly Results |
| 27 10 2023 | Quarterly Results |
| 30 01 2024 | Quarterly Results |
| 23 10 2024 | Quarterly Results |
| 28 01 2025 | Quarterly Results |
| 14 05 2025 | Final Dividend & Audited Results |
| 28 07 2025 | Quarterly Results |
| 05 11 2025 | Quarterly Results |
| 28 01 2026 | Quarterly Results |
| 28 04 2026 | Audited Results |
News
Piramal Pharma posts Rs 8.82 crore consolidated net loss in Q4FY26
Consolidated total income of the company increased by 0.06% at Rs 2,797.83 crore for Q4FY26
Piramal Pharma gets EIR with VAI for USA manufacturing facility
The receipt of said EIR marks successful closure of the inspection
Piramal Pharma’s arm completes acquisition of ‘Kenalog’
Piramal Critical Care B.V. has successfully completed the acquisition of ‘Kenalog’ from Bristol-Myers Squibb Company
USFDA concludes GMP inspection at Piramal Pharma’s Telangana facility
At the conclusion of the inspection, the US FDA issued a Form-483, with 4 observations
Piramal Pharma’s arm, Blue-Zone collaborate to recycle waste anaesthetic gases
PCC will process captured waste anaesthetic gas using BlueZone’s technology to produce Sevoflurane USP for human use in Canada
Piramal Pharma reports consolidated net loss of Rs 136.19 crore in Q3
Total consolidated income of the company decreased by 1.50% at Rs 2,183.11 crore for Q3FY26
Piramal Pharma’s arm inks pacts to acquire ‘Kenalog’ from BMS
The said acquisition is expected to further leverage the company’s extensive distribution network spanning across 6,000 plus hospitals in more than 100 countries
USFDA concludes GMP inspection at Piramal Pharma’s USA facility
At the conclusion of the inspection, the USFDA issued a Form-483, with four observations
Piramal Pharma Solutions, NewAmsterdam Pharma open OSD form suite at Sellersville facility
This addition will increase operational efficiency, helping NewAmsterdam Pharma to deliver its investigational drug therapy, if approved, to patients in need
Piramal Pharma reports consolidated net loss of Rs 81.70 crore in Q1
The consolidated total income of the company increased by 1.09% at Rs 1992.11 crore for Q1FY26
USFDA concludes GMP inspection at Piramal Pharma’s Canada facility
The inspection was completed successfully with Zero Form - 483 observations
Piramal Pharma reports 51.57% rise in Q4 consolidated net profit
The total consolidated income of the company increased by 8.43% at Rs 2,796.10 crore for Q4FY25
Piramal Pharma receives EIR from USFDA for Turbhe facility
The company has received the EIR for its Turbhe facility
Piramal Pharma’s arm inks pact with PPL Pharma
The Transaction is expected to be completed within a period of around 6 months approximately
Piramal Finance partners with ICICI Bank
Through this partnership, the company combines its innovative ‘High Tech + High Touch’ approach with the financial and banking expertise of ICICI Bank
Piramal Pharma commences commercial production of Sevoflurane at Telangana facility
This would boost the company’s capability to also tap into inhalation anesthesia opportunities in the ROW markets in addition to the USA markets
Piramal Pharma’s arm, BPCO get UKMHRA approval for Neoatricon in UK
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
USFDA concludes General GMP inspection at Turbhe facility of Piramal Pharma
On conclusion of the inspection, a Form-483 was issued with 6 observations
Piramal Pharma’s division launches Chlorpromazine Hydrochloride for Injection, USP
With this launch, PCC continues to expand their generic injectables portfolio
Piramal Pharma reports over 4-fold jump in Q2 consolidated net profit
Consolidated total income of the company increased by 17.46% at Rs 2302.86 crore for Q2FY25
Piramal Pharma’s PPS business to invest $80 million to expand Kentucky facility
Upon completion of the expansion in Q1 of 2027, this capacity will increase to over 240 annual batches
Piramal Pharma gets SBTi approval for GHG Commitment
Piramal Pharma has committed to reduce absolute scope 1 and 2 GHG emissions 42% by FY2030 from a FY2022 base year
Piramal Pharma’s consumer products division forays into men’s grooming segment
The launch of BOHEM aligns with the company’s long-standing desire to cater to the male grooming market
USFDA conducts PAI inspection at Piramal Pharma’s USA facility
On conclusion of the inspection, a Form-483 was issued with 2 observations
USFDA conducts PAI inspection at Piramal Pharma’s USA facility
On conclusion of the inspection, a Form-483 was issued with 3 observations
Piramal Pharma’s division launches new concentration of Zinc Sulfate for Injection in U.S.
The launch will enable PCC to further expand their existing Zinc Sulfate Injection product line and overall the generic injectables portfolio
Piramal Pharma gets EIR for manufacturing facility in USA
The inspection has now been successfully closed by the USFDA
Piramal Pharma’s PPS business launches high-throughput screening facility
This new expansion significantly adds primary and secondary screening capabilities of compounds prepared at the Ahmedabad site
USFDA conducts GMP Inspection at Piramal Pharma’s Bethlehem facility
On conclusion of the inspection, a Form-483 was issued with 2 observations
Piramal Pharma gets Sebi’s nod to raise up to Rs 1,050 crore through rights issue of shares
Proceeds of the issue will be utilised for payment of debt and general corporate purposes
Piramal Pharma reports 75% fall in Q4 consolidated net profit
Total consolidated income of the company decreased by 0.97% at Rs 2,188.08 crore for Q4FY23
USFDA issues EIR to Piramal Pharma’s USA facility
The inspection has now been successfully closed by the USFDA
Piramal Pharma reports consolidated net loss of Rs 90.18 crore in Q3FY23
Total consolidated income of the company increased by 5.81% to Rs 1,798.51 crore for Q3FY23
USFDA conducts PAI and GMP inspection at Piramal Pharma’s Lexington facility
At the conclusion of the inspection, the USFDA issued a Form-483, with six observations
Piramal Pharma reports consolidated net loss of Rs 37.34 crore in Q2FY23
Total consolidated income of the company increased by 10.70% to Rs 1,766.23 crore for Q2FY23
